COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM

被引：0

作者：

Tilling, C. ^{[1
]}

Evans, L. M. ^{[2
]}

Keech, M. ^{[3
]}

机构：

[1] Sanofi Aventis, Guildford, Surrey, England

[2] Univ Hosp Llandough, Penarth, S Glam, Wales

[3] Pharmakos, St Albans, England

来源：

VALUE IN HEALTH | 2011年 / 14卷 / 03期

关键词：

D O I：

10.1016/j.jval.2011.02.536

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A96 / A96

页数：1

共 50 条

[31] LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE-2 DIABETES PATIENTS ON BASAL-BOLUS THERAPY UNDER REAL WORLD CONDITIONS IN GERMANY
Bierwirth, R.
Kohlmann, T.
Dippel, F. W.
Landgraf, W.
Holle, R.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A408 - A408
[32] COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUS®) VERSUS INSULIN DETEMIR (LEVEMIR®) TREAT-TO-TARGET (L2T3) STUDY
Schaedlich, P. K.
Koltermann, K. C.
Dippel, F. W.
Hagenmeyer, E. G.
Haeussler, B.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
[33] EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING: A MODELING STUDY BASED ON THE PREDICTIVE STUDY
Yang, L.
Lay, A. L.
Chang, J. H.
[J]. VALUE IN HEALTH, 2011, 14 (03) : A97 - A97
[34] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
Kostyuk, A.
Akanov, A.
Almadiyeva, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
[35] The effect of long-acting insulin analogues, glargine or detemir, in Type 2 diabetes
Dissanayake, S.
Balakrisna-Rao, P.
Ahmed, A. B.
[J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
[36] COST-EFFECTIVENESS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE IN A BASAL-BOLUS REGIMEN IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN THE UNITED KINGDOM
Chubb, B.
Evans, M.
Wolden, M.
Christensen, T.
Gundgaard, J.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
[37] Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D)
Heller, Simon R.
Devries, J. Hans
Wysham, Carol H.
Hansen, Charlotte T.
Hansen, Melissa V.
Frier, Brian M.
[J]. DIABETES, 2018, 67
[38] Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D)
Huet, D.
Atkin, S.
Bain, S.
Gough, S.
Shestakova, M.
Raz, I.
Blonde, L.
Meneghini, L.
Begtrup, K.
Johansen, T.
Birkeland, K.
[J]. DIABETES & METABOLISM, 2012, 38 : A102 - A102
[39] Estimating Number-Needed-to-Treat with Insulin Glargine (GLAR) Compared with NPH Insulin To Avoid a Hypoglycemic Episode in People with Type 2 Diabetes (T2D): A Meta-Analysis
Home, Philip D.
Fritsche, Andreas
Schinzel, Stefan
Massi-Benedetti, Massimo
[J]. DIABETES, 2009, 58 : A544 - A545
[40] Relationship of Insulin Dose, A1c Lowering, and Weight in Type 2 Diabetes: Comparing Insulin Glargine and Insulin Detemir
Dailey, George
Admane, Karim
Mercier, Florence
Owens, David
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (12) : 1019 - 1027

← 1 2 3 4 5 →